miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. - Test2 - elhamkhani - TriplyDB

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.

http://www.wikidata.org/entity/Q38476564

about

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment MicroRNAs in multiple myeloma and related bone disease Long non-coding RNAs in normal and malignant hematopoiesis miR-29a regulates the proliferation and differentiation of retinal progenitors by targeting Rbm8a Down-regulation of miR-29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer.Cross disease analysis of co-functional microRNA pairs on a reconstructed network of disease-gene-microRNA tripartite.miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.Circulating miR-21, miR-378, and miR-940 increase in response to an acute exhaustive exercise in chronic heart failure patients MicroRNAs interfere with DNA methylation in rheumatoid arthritis synovial fibroblasts.Chemotherapy-mediated miR-29b expression inhibits the invasion and angiogenesis of cervical cancer.DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.Biological Insights into Myeloma and Other B Cell Malignancies.MicroRNAs 29b and 181a down-regulate the expression of the norepinephrine transporter and glucocorticoid receptors in PC12 cells.Mir-221/222 are promising targets for innovative anticancer therapy.miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.Microenvironment drug resistance in multiple myeloma: emerging new players.Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.Prognostic value of the MicroRNA-29 family in multiple human cancers: A meta-analysis and systematic review.Interplay between the miRNome and the epigenetic machinery: Implications in health and disease.DNA methylation aberrancies as a guide for surveillance and treatment of human cancers.Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.MicroRNA-mediated drug resistance in ovarian cancer.Aberrant microRNA expression in tumor mycosis fungoides.Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.Long non-coding RNAs in B-cell malignancies: a comprehensive overview.miR-223 decreases cell proliferation and enhances cell apoptosis in acute myeloid leukemia via targeting FBXW7.miR-29b regulates expression of collagens I and III in chondrogenically differentiating BMSC in an osteoarthritic environment Restoration of miR-29b exerts anti-cancer effects on glioblastoma.Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.KRAS-driven miR-29b expression is required for tumor suppressor gene silencing.Modulation of ALDH5A1 and SLC22A7 by microRNA hsa-miR-29a-3p in human liver cells.Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.Downregulation of miR‑29b targets DNMT3b to suppress cellular apoptosis and enhance proliferation in pancreatic cancer.MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.MicroRNA, an Antisense RNA, in Sensing Myeloid Malignancies.

P2860

Q26765477-D814B98B-AE4D-48A8-AAE7-A727054CDF68 Q26770478-81D57B21-C168-4223-B7FA-6806D81B86BD Q28070169-20F00676-39B7-4FCF-B618-DDABEC931499 Q33761991-D61E4956-5D30-488F-9D97-87CFEAFAB0F4 Q33889273-18B7CF1E-4E37-45FD-B65E-26790B0BE7BF Q36322428-B3AFA093-4BC1-43A7-9043-A6F7004F6D00 Q36785683-E19E209F-2C40-46D2-99FC-F9E4BA467454 Q37022196-21999954-7F7F-493A-8ADA-3F0F91ACBF43 Q37356087-8DA74164-8DC6-42B5-BCFE-162E26857CF4 Q37716411-646992B6-E979-49CA-89D6-8A5CE8BFE396 Q37729405-4677B0FF-7C0E-494E-BA5D-39CE541A497C Q38264923-79E97A9E-2142-4CD4-A6F3-D7C2B141BD3F Q38685982-4C4ADF16-6A63-43F4-9D09-36AB3A8583BC Q38753094-26D41640-4271-43AF-AFA7-75C00842FFE0 Q38767024-DCC662B2-9A53-4B90-A364-EEBCA1626A8F Q38826614-CE9E8DDB-8ECC-45C4-85E3-658B42E40D32 Q38854653-97E0D751-E0F1-45AA-B6A8-DE9381673DC7 Q38913083-2554447D-6708-4E5F-87DD-A8B23CBE0FD8 Q39021977-A6C120B4-D0FD-4F10-B27E-B6E20F41FF63 Q39072517-338E6DA1-5977-40A5-ACB6-27B177C644D2 Q39098623-13BE20A3-A298-45D7-A03E-D19830CF1A60 Q39208639-6CE61D7F-4768-4521-B74F-07C0A9472E8E Q39379624-54E73390-A087-4C64-93D3-96602A40B710 Q39382756-E8A7E599-E0EA-4B9B-9B94-14495D61263B Q39395267-1EE6C92B-CF64-4F4D-8FDB-C7CF8746A253 Q39667223-7A2B4226-CEC9-4986-86F5-AEA911E12A8B Q39923951-332AF665-6BB4-453C-8F3A-8CD511FBDE38 Q41092512-1D5EEF46-DB3E-4A8C-9C0B-0C96512378FB Q41694305-379339BC-E38E-4F92-88BE-2C1DF442719A Q42064309-21F2C6AB-1943-42E0-8748-F18DA38179B4 Q42379009-386288D9-0B4E-4297-9180-2EC429F3E270 Q47095704-7D1CBB6A-BCF3-4D2D-AA52-DDF6B4143AAD Q47106247-039F1668-A5F0-4D93-81F3-B822912A5198 Q47133651-DE8902CA-12A5-4533-A391-C9524938C782 Q47141339-DECE58F6-6647-4447-91B1-887E0CA8C44C Q47149175-00712166-F02B-4ADE-A3B4-E9C7D283CAAE Q47215137-CA3171C9-4C16-4FFB-921E-2C8E479CB18B Q47328675-B4F27E72-82B0-4F04-B98E-14785B7E5177 Q47702288-9BCA9230-6F78-466A-9BB5-639548D52A9E Q49521797-84FBE035-FEA8-4A90-BC95-E90BD0694B82

P2860

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.

http://www.wikidata.org/entity/Q38476564

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

miR-29s: a family of epi-miRNA ...... s in hematologic malignancies.

@en

type

label

miR-29s: a family of epi-miRNA ...... s in hematologic malignancies.

@en

prefLabel

miR-29s: a family of epi-miRNA ...... s in hematologic malignancies.

@en

P1433

Q38476564-3A88CC64-5C8D-46FC-8234-B02D96469097

P1476

Q38476564-ADB1FE1E-4AAF-4C4F-AE9D-F1FDAEEF564B

P2093

Q38476564-02A542C1-553D-446E-8740-34683364BA55

Q38476564-6912ED19-FCE6-467A-9E35-B20A562FAD00

Q38476564-9C42AEC4-E5A5-454C-8A9C-9FE4E00FA909

Q38476564-BAEC6B0C-2892-4D4A-ADDD-28C9DD3FADE0

Q38476564-BB73CFA3-FE4E-4B76-B541-CDAF6DDA6EE7

Q38476564-E3FA99E2-5E92-4F10-A6A9-B0467D5ED0B0

P275

Q38476564-8855A268-5FDB-4F54-9CB0-8C9F490AA154

P2860

Q38476564-022AA983-5F05-4A08-A6D6-82A9ABBACF40

Q38476564-028BCED8-87A9-4D4A-ACA5-E29D2430A481

Q38476564-02F70941-3247-483A-873F-0FAE75424D74

Q38476564-02F975CB-338E-4EEE-A16D-435133E7DF96

Q38476564-033B9DBA-9B53-4A80-9816-D8D397F4146E

Q38476564-050ED956-520D-4850-AF7B-6D97D9D2F88B

Q38476564-059C11F8-9D05-4F81-A1B0-F2E3673B0007

Q38476564-05CB7268-B4D7-4D0C-AB3E-DA880DAC272E

Q38476564-06044605-F308-49F2-AA9C-19FFFE90C530

Q38476564-06BD2458-39B8-44C5-8313-126BCD04E1C4

P304

Q38476564-F712A502-20C3-426A-B6F0-5602E7C5B7AB

P31

Q38476564-619C44E8-E846-4FF6-BC8B-131ACFE71FC2

P356

Q38476564-4069569A-B401-4FEA-8E88-37ECD99ED7BB

P407

Q38476564-8069E4F6-36BF-4479-AC9D-D82A0E53AA81

P433

Q38476564-2088BF40-3D18-4789-8119-144FA0ED5CFD

P478

Q38476564-5A1A581C-06AE-4A2E-AE56-327ECBDDBB3E

P50

Q38476564-12D34811-2359-422A-904F-54A7E35DE917

P5008

Q38476564-2470E9A6-DBDF-4329-A555-ED7B4CE59C91

P577

Q38476564-74F5FF77-F39C-4734-81E1-CED7E013E653

P698

Q38476564-7C5E7522-6DFF-4999-8DE2-FD4DC9746FC0

P921

Q38476564-14873B6E-326E-4691-8A50-BCD43694B86B

P932

Q38476564-F2392719-5820-4BA4-BC3D-8EAE4D397F32

P356

ONCOTARGET.3805

P1433

P1476

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies

@en

P2093

Lavinia Raimondi

http://www.w3.org/2001/XMLSchema#string

Marco Rossi

http://www.w3.org/2001/XMLSchema#string

Maria Rita Pitari

http://www.w3.org/2001/XMLSchema#string

Nicola Amodio

http://www.w3.org/2001/XMLSchema#string

Pierfrancesco Tassone

http://www.w3.org/2001/XMLSchema#string

Pierosandro Tagliaferri

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation

MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1

Hallmarks of Cancer: The Next Generation

Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

Histone deacetylases (HDACs): characterization of the classical HDAC family

Numerous microRNPs in neuronal cells containing novel microRNAs

MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias

MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B

An operational definition of epigenetics

P304

12837-12861

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.3805

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25968566

http://www.w3.org/2001/XMLSchema#string

P921

hematologic cancer

P932

4536984

http://www.w3.org/2001/XMLSchema#string